Quick Answer
Silo Pharma, Inc. reported R&D Expense of $2.16 million for fiscal year 2025.
Silo Pharma, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.16M | -8.8% |
| 2024 | $2.37M | +180.2% |
| 2023 | $845.1K | -34.3% |
| 2022 | $1.29M | +85.4% |
| 2021 | $693.9K | +2543.5% |
| 2020 | $26.2K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $543.6K | +5.0% | -24.2% |
| June 30, 2025 | $717.2K | +82.6% | +20.8% |
| March 31, 2025 | $594.0K | +86.6% | +14.8% |
| September 30, 2024 | $517.5K | +196.6% | +31.8% |
| June 30, 2024 | $392.8K | +200.5% | +23.4% |
| March 31, 2024 | $318.2K | +56.8% | +82.4% |
| September 30, 2023 | $174.5K | -53.6% | +33.5% |
| June 30, 2023 | $130.7K | +23.7% | -35.6% |
- Silo Pharma, Inc. showed a decrease of -8.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Silo Pharma, Inc.’s r&d expense has grown by 8131.7% (from $26.2 thousand to $2.16 million).
- The most recent figure is from Silo Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: